Bio-Techne vs Becton Dickinson and: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Bio-Techne Corp (TECH)

Q3 202628 Jun – 23 Sep 2026

▲3

Bio-Techne's $73-a-share Merck buyout clears shareholder vote and antitrust review

Shareholders approve Merck KGaA buyout On September 23, 2026, Bio-Techne shareholders voted to approve the $73-per-share cash buyout by Merck KGaA. This locks in the deal price and moves the company closer to closing, so the stock should trade near $73 rather than on its own business results.
This is the latest and most important step in the buyout that now defines TECH's price.
Antitrust waiting period expires The U.S. antitrust waiting period under the Hart-Scott-Rodino Act expired on September 18, 2026. That removes a major regulatory hurdle, making it more likely the deal closes on schedule and reducing the risk that the $73 price falls through.
It is a new, concrete regulatory clearance that directly supports deal completion.
Merck KGaA confirms deal on track Merck KGaA raised its 2026 outlook on August 6 and said it still expects to close the Bio-Techne purchase by late 2026 or early 2027, with about 140 million euros in annual cost savings. A healthy buyer with a firm timeline makes the $73 payout more certain.
It shows the acquirer is financially strong and committed, which supports the deal price.
Weak quarterly sales and legal probe Bio-Techne's revenue fell 1.5% to $311.4 million, missing estimates, and a law firm is investigating whether the board handled the buyout fairly. These are minor now because the $73 cash deal caps the stock, but they could matter if the deal breaks.
It gives the fair counterweight: the company's own results are soft and the deal faces a legal review.

August 202628 Jun – 23 Sep 2026

▲3

Bio-Techne's $73-a-share Merck buyout clears shareholder vote and antitrust review

Shareholders approve Merck KGaA buyout On September 23, 2026, Bio-Techne shareholders voted to approve the $73-per-share cash buyout by Merck KGaA. This locks in the deal price and moves the company closer to closing, so the stock should trade near $73 rather than on its own business results.
This is the latest and most important step in the buyout that now defines TECH's price.
Antitrust waiting period expires The U.S. antitrust waiting period under the Hart-Scott-Rodino Act expired on September 18, 2026. That removes a major regulatory hurdle, making it more likely the deal closes on schedule and reducing the risk that the $73 price falls through.
It is a new, concrete regulatory clearance that directly supports deal completion.
Merck KGaA confirms deal on track Merck KGaA raised its 2026 outlook on August 6 and said it still expects to close the Bio-Techne purchase by late 2026 or early 2027, with about 140 million euros in annual cost savings. A healthy buyer with a firm timeline makes the $73 payout more certain.
It shows the acquirer is financially strong and committed, which supports the deal price.
Weak quarterly sales and legal probe Bio-Techne's revenue fell 1.5% to $311.4 million, missing estimates, and a law firm is investigating whether the board handled the buyout fairly. These are minor now because the $73 cash deal caps the stock, but they could matter if the deal breaks.
It gives the fair counterweight: the company's own results are soft and the deal faces a legal review.

Latest28 Jun – 23 Sep 2026

▲3

Bio-Techne's $73-a-share Merck buyout clears shareholder vote and antitrust review

Shareholders approve Merck KGaA buyout On September 23, 2026, Bio-Techne shareholders voted to approve the $73-per-share cash buyout by Merck KGaA. This locks in the deal price and moves the company closer to closing, so the stock should trade near $73 rather than on its own business results.
This is the latest and most important step in the buyout that now defines TECH's price.
Antitrust waiting period expires The U.S. antitrust waiting period under the Hart-Scott-Rodino Act expired on September 18, 2026. That removes a major regulatory hurdle, making it more likely the deal closes on schedule and reducing the risk that the $73 price falls through.
It is a new, concrete regulatory clearance that directly supports deal completion.
Merck KGaA confirms deal on track Merck KGaA raised its 2026 outlook on August 6 and said it still expects to close the Bio-Techne purchase by late 2026 or early 2027, with about 140 million euros in annual cost savings. A healthy buyer with a firm timeline makes the $73 payout more certain.
It shows the acquirer is financially strong and committed, which supports the deal price.
Weak quarterly sales and legal probe Bio-Techne's revenue fell 1.5% to $311.4 million, missing estimates, and a law firm is investigating whether the board handled the buyout fairly. These are minor now because the $73 cash deal caps the stock, but they could matter if the deal breaks.
It gives the fair counterweight: the company's own results are soft and the deal faces a legal review.

Q2 202625 Jun – 26 Jun 2026

▲1▼1

Merck KGaA to buy Bio-Techne for $73/share in $11.3B cash deal

Merck KGaA acquisition at $73/share cash Germany's Merck KGaA agreed to acquire Bio-Techne for $73 per share in cash, a 36% premium to its recent average price. This puts a firm floor under the stock near the deal price and is the main reason shares jumped about 20%.
This is the single new event that explains the stock's move and future path.
Deal completion risk and timeline The deal needs regulatory approvals and a shareholder vote, and is expected to close in late 2026 or early 2027. Until then, the stock may trade below $73 if investors worry the deal could fall through, but the agreed price limits big downside.
It is the main counterweight: the deal is not yet final, so the premium is not guaranteed.
Weak underlying quarterly revenue Bio-Techne's latest quarterly revenue fell 1.5% to $311.4 million and missed expectations. This weak operating performance is now less important because the company is being bought, but it shows why the standalone business was struggling.
It explains the weak standalone backdrop that the buyout overrides, giving a fair picture.

June 202625 Jun – 26 Jun 2026

▲1▼1

Merck KGaA to buy Bio-Techne for $73/share in $11.3B cash deal

Merck KGaA acquisition at $73/share cash Germany's Merck KGaA agreed to acquire Bio-Techne for $73 per share in cash, a 36% premium to its recent average price. This puts a firm floor under the stock near the deal price and is the main reason shares jumped about 20%.
This is the single new event that explains the stock's move and future path.
Deal completion risk and timeline The deal needs regulatory approvals and a shareholder vote, and is expected to close in late 2026 or early 2027. Until then, the stock may trade below $73 if investors worry the deal could fall through, but the agreed price limits big downside.
It is the main counterweight: the deal is not yet final, so the premium is not guaranteed.
Weak underlying quarterly revenue Bio-Techne's latest quarterly revenue fell 1.5% to $311.4 million and missed expectations. This weak operating performance is now less important because the company is being bought, but it shows why the standalone business was struggling.
It explains the weak standalone backdrop that the buyout overrides, giving a fair picture.

25 Jun – 26 Jun 2026

▲1▼1

Merck KGaA to buy Bio-Techne for $73/share in $11.3B cash deal

Merck KGaA acquisition at $73/share cash Germany's Merck KGaA agreed to acquire Bio-Techne for $73 per share in cash, a 36% premium to its recent average price. This puts a firm floor under the stock near the deal price and is the main reason shares jumped about 20%.
This is the single new event that explains the stock's move and future path.
Deal completion risk and timeline The deal needs regulatory approvals and a shareholder vote, and is expected to close in late 2026 or early 2027. Until then, the stock may trade below $73 if investors worry the deal could fall through, but the agreed price limits big downside.
It is the main counterweight: the deal is not yet final, so the premium is not guaranteed.
Weak underlying quarterly revenue Bio-Techne's latest quarterly revenue fell 1.5% to $311.4 million and missed expectations. This weak operating performance is now less important because the company is being bought, but it shows why the standalone business was struggling.
It explains the weak standalone backdrop that the buyout overrides, giving a fair picture.

Becton Dickinson and Company (BDX)

Q3 202630 Jul – 6 Oct 2026

▲4

BD Beats Q3, Expands GLP-1 Delivery and U.S. Manufacturing

Q3 earnings and revenue beat BD reported Q3 adjusted EPS of $3.23 and revenue of $4.98 billion, both above estimates, with growth across all four segments. The beat and narrowed full-year guidance reassured investors, pushing shares up nearly 7% and supporting the stock price.
This is the core financial result that directly moved BDX shares and confirms business momentum.
GLP-1 delivery partnerships BD announced new GLP-1 delivery partnerships, including a semaglutide pen collaboration in Brazil using its Vystra Injection Pen platform. This opens a growing market for chronic disease treatment, boosting future revenue prospects and investor optimism.
It highlights a new growth avenue that can drive future sales and supports the positive stock reaction.
Vmax 160 pharmacy robot deployment BD deployed its next-generation Vmax 160 pharmacy automation robot at Fairview Health Services, the first U.S. health system to adopt it. This showcases BD's technology leadership in pharmacy automation, potentially driving future orders and lifting the stock.
It demonstrates product innovation and adoption, a positive signal for future revenue and competitive positioning.
$19 billion U.S. manufacturing expansion and tariff shield BD pledged $19 billion to expand U.S. manufacturing, including $3 billion for facilities, and secured an agreement that shields it from future Section 232 tariffs on specified products. This reduces tariff risk and strengthens domestic supply chain, supporting the stock.
It addresses a major external risk (tariffs) and shows long-term commitment, directly impacting BDX's cost structure and pricing power.

September 202630 Jul – 6 Oct 2026

▲4

BD Beats Q3, Expands GLP-1 Delivery and U.S. Manufacturing

Q3 earnings and revenue beat BD reported Q3 adjusted EPS of $3.23 and revenue of $4.98 billion, both above estimates, with growth across all four segments. The beat and narrowed full-year guidance reassured investors, pushing shares up nearly 7% and supporting the stock price.
This is the core financial result that directly moved BDX shares and confirms business momentum.
GLP-1 delivery partnerships BD announced new GLP-1 delivery partnerships, including a semaglutide pen collaboration in Brazil using its Vystra Injection Pen platform. This opens a growing market for chronic disease treatment, boosting future revenue prospects and investor optimism.
It highlights a new growth avenue that can drive future sales and supports the positive stock reaction.
Vmax 160 pharmacy robot deployment BD deployed its next-generation Vmax 160 pharmacy automation robot at Fairview Health Services, the first U.S. health system to adopt it. This showcases BD's technology leadership in pharmacy automation, potentially driving future orders and lifting the stock.
It demonstrates product innovation and adoption, a positive signal for future revenue and competitive positioning.
$19 billion U.S. manufacturing expansion and tariff shield BD pledged $19 billion to expand U.S. manufacturing, including $3 billion for facilities, and secured an agreement that shields it from future Section 232 tariffs on specified products. This reduces tariff risk and strengthens domestic supply chain, supporting the stock.
It addresses a major external risk (tariffs) and shows long-term commitment, directly impacting BDX's cost structure and pricing power.

Latest30 Jul – 6 Oct 2026

▲4

BD Beats Q3, Expands GLP-1 Delivery and U.S. Manufacturing

Q3 earnings and revenue beat BD reported Q3 adjusted EPS of $3.23 and revenue of $4.98 billion, both above estimates, with growth across all four segments. The beat and narrowed full-year guidance reassured investors, pushing shares up nearly 7% and supporting the stock price.
This is the core financial result that directly moved BDX shares and confirms business momentum.
GLP-1 delivery partnerships BD announced new GLP-1 delivery partnerships, including a semaglutide pen collaboration in Brazil using its Vystra Injection Pen platform. This opens a growing market for chronic disease treatment, boosting future revenue prospects and investor optimism.
It highlights a new growth avenue that can drive future sales and supports the positive stock reaction.
Vmax 160 pharmacy robot deployment BD deployed its next-generation Vmax 160 pharmacy automation robot at Fairview Health Services, the first U.S. health system to adopt it. This showcases BD's technology leadership in pharmacy automation, potentially driving future orders and lifting the stock.
It demonstrates product innovation and adoption, a positive signal for future revenue and competitive positioning.
$19 billion U.S. manufacturing expansion and tariff shield BD pledged $19 billion to expand U.S. manufacturing, including $3 billion for facilities, and secured an agreement that shields it from future Section 232 tariffs on specified products. This reduces tariff risk and strengthens domestic supply chain, supporting the stock.
It addresses a major external risk (tariffs) and shows long-term commitment, directly impacting BDX's cost structure and pricing power.